[1]
|
Levine, A.J. and Puzio-Kuter, A.M. (2010) The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes. Science, 330, 1340-1344. https://doi.org/10.1126/science.1193494
|
[2]
|
Deberardinis, R.J. and Chandel, N.S. (2016) Fundamentals of Cancer Metabolism. Science Advances, 2, e1600200. https://doi.org/10.1126/sciadv.1600200
|
[3]
|
Wettersten, H.I. (2020) Reprogramming of Metabolism in Kidney Cancer. Seminars in Nephrology, 40, 2-13. https://doi.org/10.1016/j.semnephrol.2019.12.002
|
[4]
|
Pavlova, N.N. and Thompson, C.B. (2016) The Emerging Hallmarks of Cancer Metabolism. Cell Metabolism, 23, 27-47. https://doi.org/10.1016/j.cmet.2015.12.006
|
[5]
|
Petrella, B.L. and Brinckerhoff, C.E. (2009) PTEN Suppression of YY1 Induces HIF-2 Activity in Von Hippel Lindau Null Renal Cell Carcinoma. Cancer Biology & Therapy, 8, 1389-1401. https://doi.org/10.4161/cbt.8.14.8880
|
[6]
|
Chakraborty, S., Balan, M., Sabarwal, A., et al. (2021) Metabolic Reprogramming in Renal Cancer: Events of a Metabolic Disease. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1876, Article 188559. https://doi.org/10.1016/j.bbcan.2021.188559
|
[7]
|
Metallo, C.M., Gameiro, P.A., Bell, E.L., et al. (2012) Reductive Glutamine Metabolism by IDH1 Mediates Lipogenesis under Hypoxia. Nature, 481, 380-384. https://doi.org/10.1038/nature10602
|
[8]
|
Mullen, A.R. (2012) Reductive Carboxylation Supports Growth in Tumour Cells with Defective Mitochondria. Nature, 481, 385-388. https://doi.org/10.1038/nature10642
|
[9]
|
Ozcan, A., Shen, S.S., Zhai, Q.J., et al. (2007) Expression of GLUT1 in Primary Renal Tumors: Morphologic and Biologic Implications. American Journal of Clinical Pathology, 128, 245-254. https://doi.org/10.1309/HV6NJVRQKK4QHM9F
|
[10]
|
Courtney, K.D., Bezwada, D., Mashimo, T., et al. (2018) Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation in Vivo. Cell Metabolism, 28, 793-800. https://doi.org/10.1016/j.cmet.2018.07.020
|
[11]
|
Singer, K., Kastenberger, M., Gottfried, E., et al. (2011) Warburg Phenotype in Renal Cell Carcinoma: High Expression of Glucose-Transporter 1 (GLUT-1) Correlates with Low CD8 T-Cell Infiltration in the Tumor. International Journal of Cancer, 128, 2085-2095. https://doi.org/10.1002/ijc.25543
|
[12]
|
Fischer, K., Hoffmann, P., Voelkl, S., et al. (2007) Inhibitory Effect of Tumor Cell-Derived Lactic Acid on Human T Cells. Blood, 109, 3812-3819. https://doi.org/10.1182/blood-2006-07-035972
|
[13]
|
Chan, D.A., Sutphin, P.D., Nguyen, P., et al. (2011) Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality. Science Translational Medicine, 3, 94ra70. https://doi.org/10.1126/scitranslmed.3002394
|
[14]
|
Hakimi, A.A., Reznik, E., Lee, C.-H., et al. (2016) An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell, 29,104-116. https://doi.org/10.1016/j.ccell.2015.12.004
|
[15]
|
Mandriota, S.J. (2002) HIF Activation Identifies Early Lesions in VHL Kidneys: Evidence for Site-Specific Tumor Suppressor Function in the Nephron. Cancer Cell, 1, 459-468. https://doi.org/10.1016/S1535-6108(02)00071-5
|
[16]
|
Semenza, G.L. (2009) Regulation of Cancer Cell Metabolism by Hypoxia-Inducible Factor 1. Seminars in Cancer Biology, 19, 12-16. https://doi.org/10.1016/j.semcancer.2008.11.009
|
[17]
|
Semenza, G.L. (2010) HIF-1: Upstream and Downstream of Cancer Metabolism. Current Opinion in Genetics & Development, 20, 51-56. https://doi.org/10.1016/j.gde.2009.10.009
|
[18]
|
Kim, J.W., Tchernyshyov, I., Semenza, G.L., et al. (2006) HIF-1-Mediated Expression of Pyruvate Dehydrogenase Kinase: A Metabolic Switch Required for Cellular Adaptation to Hypoxia. Cell Metabolism, 3, 177-185. https://doi.org/10.1016/j.cmet.2006.02.002
|
[19]
|
Tan, Z., Luo, X., Xiao, L., et al. (2016) The Role of PGC1alpha in Cancer Metabolism and Its Therapeutic Implications. Molecular Cancer Therapeutics, 15, 774-782. https://doi.org/10.1158/1535-7163.MCT-15-0621
|
[20]
|
Wettersten, H.I., Hakimi, A.A., Morin, D., Bianchi, C., Johnstone, M.E., Donohoe, D.R., Trott, J.F., Aboud, O.A., Stirdivant, S., Neri, B., Wolfert, R., Stewart, B., Perego, R., Hsieh, J.J. and Weiss, R.H. (2015) Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Research, 75, 2541-2552. https://doi.org/10.1158/0008-5472.CAN-14-1703
|
[21]
|
Perroud, B., Ishimaru, T., Borowsky, A.D. and Weiss, R.H. (2008) Grade-Dependent Proteomics Characterization of Kidney Cancer. Molecular & Cellular Proteomics, 8, 971-985. https://doi.org/10.1074/mcp.M800252-MCP200
|
[22]
|
Yang, Y., Valera, V., Sourbier, C., et al. (2012) A Novel Fumarate Hydratase-Deficient HLRCC Kidney Cancer Cell Line, UOK268: A Model of the Warburg Effect in Cancer. Cancer Genetics, 205, 377-390. https://doi.org/10.1016/j.cancergen.2012.05.001
|
[23]
|
Rohrig, F. and Schulze, A. (2016) The Multifaceted Roles of Fatty Acid Synthesis in Cancer. Nature Reviews Cancer, 16, 732-749. https://doi.org/10.1038/nrc.2016.89
|
[24]
|
Pandey, P.R., Liu, W., Xing, F., et al. (2012) Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS). Recent Patents on Anti-Cancer Drug Discovery, 7, 185-197. https://doi.org/10.2174/157489212799972891
|
[25]
|
Gebhard, R.L., Clayman, R.V., Prigge, W.F., et al. (1987) Abnormal Cholesterol Metabolism in Renal Clear Cell Carcinoma. Journal of Lipid Research, 28, 1177-1184. https://doi.org/10.1016/S0022-2275(20)38606-5
|
[26]
|
Qiu, B., Ackerman, D., Sanchez, D.J., Simon, M.C., et al. (2015) HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 5, 652-667. https://doi.org/10.1158/2159-8290.CD-14-1507
|
[27]
|
Horiguchi, A., Asano, T., Asano, T., Sumitomo, M., Hayakawa, M., et al. (2008) Fatty Acid Synthase over Expression Is an Indicator of Tumor Aggressiveness and Poor Prognosis in Renal Cell Carcinoma. The Journal of Urology, 180, 1137-1140. https://doi.org/10.1016/j.juro.2008.04.135
|
[28]
|
Von Roemeling, C.A., Marlow, L.A., Wei, J.J., Copland, J.A., et al. (2013) Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 19, 2368-2380. https://doi.org/10.1158/1078-0432.CCR-12-3249
|
[29]
|
Mungan, M.U., Gurel, D., Canda, A.E., et al. (2006) Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma. European Urology, 50, 92-97. https://doi.org/10.1016/j.eururo.2005.12.039
|
[30]
|
Tabriz, H.M., Mirzaalizadeh, M., Gooran, S., et al. (2016) COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis. Asian Pacific Organization for Cancer Prevention, 17, 535-538. https://doi.org/10.7314/APJCP.2016.17.2.535
|
[31]
|
Wettersten, H.I., Aboud, O.A., Lara, P.N., et al. (2017) Metabolic Reprogramming in Clear Cell Renal Cell Carcinoma. Nature Reviews Nephrology, 13, 410-419. https://doi.org/10.1038/nrneph.2017.59
|
[32]
|
Li, H., Bullock, K., Gurjao, C., et al. (2019) Metabolomic Adaptations and Correlates of Survival to Immune Checkpoint Blockade. Nature Communications, 10, Article No. 4346. https://doi.org/10.1038/s41467-019-12361-9
|
[33]
|
Hassanein, M., Hoeksema, M.D., Shiota, M., et al. (2013) SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival. Clinical Cancer Research, 19, 560-570. https://doi.org/10.1158/1078-0432.CCR-12-2334
|
[34]
|
Matés, J.M., Segura, J.A., Martín-Rufián, M., et al. (2013) Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress against Cancer. Current Molecular Medicine, 13, 514-534. https://doi.org/10.2174/1566524011313040005
|
[35]
|
Mannava, S., Grachtchouk, V., Wheeler, L.J., Im, M., Zhuang, D., et al. (2008) Direct Role of Nucleotide Metabolism in C-MYC-Dependent Proliferation of Melanoma Cells. Cell Cycle, 7, 2392-2400. https://doi.org/10.4161/cc.6390
|
[36]
|
Shroff, E.H., Eberlin, L.S., Dang, V.M., et al. (2015) MYC Oncogene Overexpression Drives Renal Cell Carcinoma in a Mouse Model through Glutamine Metabolism. Proceedings of the National Academy of Sciences, 112, 6539-6544. https://doi.org/10.1073/pnas.1507228112
|
[37]
|
Bowles, T.L., Kim, R., Galante, J., et al. (2008) Pancreatic Cancer Cell Lines Deficient in Argininosuccinate Synthetase Are Sensitive to Arginine Deprivation by Arginine Deiminase. International Journal of Cancer, 123, 1950-1955. https://doi.org/10.1002/ijc.23723
|
[38]
|
Ensor, C.M., Holtsberg, F.W., Bomalaski, J.S., et al. (2002) Pegylated Arginine Deiminase (ADI-SS PEG20,000 mw) Inhibits Human Melanomas and Hepatocellular Carcinomas in vitro and in vivo. Cancer Research, 62, 5443-5450.
|
[39]
|
Yoon, C.-Y., Shim, Y.-J., Kim, E.-H., et al. (2007) Renal Cell Carcinoma Does Not Express Argininosuccinate Synthetase and Is Highly Sensitive to Arginine Deprivation via Arginine Deiminase. International Journal of Cancer, 120, 897-905. https://doi.org/10.1002/ijc.22322
|
[40]
|
Rabinovich, S., Adler, L., Yizhak, K., et al. (2015) Diversion of Aspartate in ASS1-Deficient Tumours Fosters de novo Pyrimidine Synthesis. Nature, 527, 379-383. https://doi.org/10.1038/nature15529
|
[41]
|
Yoon, J.K., Frankel, A.E., Feun, L.G., et al. (2013) Arginine Deprivation Therapy for Malignant Melanoma. Clinical Pharmacology: Advances and Applications, 5, 11-19. https://doi.org/10.2147/CPAA.S37350
|
[42]
|
Jiang, P., Du, W. and Wu, M. (2014) Regulation of the Pentose Phosphate Pathway in Cancer. Protein & Cell, 5, 592-602. https://doi.org/10.1007/s13238-014-0082-8
|
[43]
|
Aykin-Burns, N., Ahmad, I.M., Zhu, Y., et al. (2009) Increased Levels of Superoxide and H2O2 Mediate the Differential Susceptibility of Cancer Cells versus Normal Cells to Glucose Deprivation. Biochemical Journal, 418, 29-37. https://doi.org/10.1042/BJ20081258
|
[44]
|
Nogueira, V. and Hay, N. (2013) Molecular Pathways: Reactive Oxygen Species Homeostasis in Cancer Cells and Implications for Cancer Therapy. Clinical Cancer Research, 19, 4309-4314. https://doi.org/10.1158/1078-0432.CCR-12-1424
|
[45]
|
Langbein, S., Frederiks, W.M., Hausen, A.Z., et al. (2008) Metastasis Is Promoted by a Bioenergetic Switch: New Targets for Progressive Renal Cell Cancer. International Journal of Cancer, 122, 2422-2428. https://doi.org/10.1002/ijc.23403
|
[46]
|
Lucarelli, G., Galleggiante, V., Rutigliano, M., et al. (2015) Metabolomic Profile of Glycolysis and the Pentose Phosphate Pathway Identifies the Central Role of Glucose-6-Phosphate Dehydrogenase in Clear Cell-Renal Cell Carcinoma. Oncotarget, 6, 13371-13386. https://doi.org/10.18632/oncotarget.3823
|
[47]
|
Schmidinger, M. (2013) Understanding and Managing Toxicities of Vascular Endothelial Growth Factor (VEGF) Inhibitors. European Journal of Cancer Supplements, 11, 172-191. https://doi.org/10.1016/j.ejcsup.2013.07.016
|
[48]
|
Chen, W., Hill, H., Christie, A., et al. (2016) Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. Nature, 539, 112-117. https://doi.org/10.1038/nature19796
|
[49]
|
Gross, M.I., Demo, S.D., et al. (2014) Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 13, 890-901. https://doi.org/10.1158/1535-7163.MCT-13-0870
|
[50]
|
Trott, J.F., Kim, J., et al. (2016) Inhibiting Tryptophan Metabolism Enhances Interferon Therapy in Kidney Cancer. Oncotarget, 7, 66540-66557. https://doi.org/10.18632/oncotarget.11658
|
[51]
|
Benita, Y., Kikuchi, H., Smith, A.D., et al. (2009) An Integrative Genomics Approach Identifies Hypoxia Inducible Factor-1 (HIF-1)-Target Genes that form the Core Response to Hypoxia. Nucleic Acids Research, 37, 4587-4602. https://doi.org/10.1093/nar/gkp425
|